Uptake of novel medical therapies in the general population

Current Oncology

Volumn 18, Issue 3, 2011, Pages 105-108

  Booth, C M ^a   Rapoport, B ^b  

^a QUEEN S UNIVERSITY   (Canada)

^b Medical Oncology Centre of Rosebank   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE DERIVATIVE; CYCLOPHOSPHAMIDE; DOCETAXEL; FLUOROURACIL; GRANULOCYTE COLONY STIMULATING FACTOR; METHOTREXATE; PLACEBO; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

BREAST CANCER; CANADA; CANCER ADJUVANT THERAPY; CANCER RESEARCH; DISEASE FREE SURVIVAL; EDITORIAL; FEBRILE NEUTROPENIA; HUMAN; MORTALITY; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT OUTCOME;

EID: 79959311790     PISSN: None     EISSN: 17187729     Source Type: Journal    
DOI: 10.3747/co.v18i3.858     Document Type: Editorial

References (21)

1. Dans AL, Dans LF, Guyatt GH, Richardson S. Users' guides to the medical literature: xiv. How to decide on the applicability of clinical trial results to your patient. Evidence-Based Medicine Working Group. JAMA 1998;279:545-9.
2. Madarnas Y, Dent SF, Husain SF, et al. Real-world experience with adjuvant fec-d chemotherapy in four Ontario regional cancer centres. Curr Oncol 2011;18:119-25.
3. Roché H, Fumoleau P, Spielmann M, et al. Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients: the fnclcc pacs 01 trial. J Clin Oncol 2006;24:5664-71.
4. Guyatt GH, Sackett DL, Cook DJ. Users' guides to the medical literature. II. How to use an article about therapy or prevention. A. Are the results of the study valid? Evidence-Based Medicine Working Group. JAMA 1993;270:2598-601.
5. Meyer RM. Generalizing the results of cancer clinical trials. J Clin Oncol 2010;28:187-9.
6. Wen SW, Kramer MS. Uses of ecologic studies in the assessment of intended treatment effects. J Clin Epidemiol 1999;52:7-12.
7. Booth CM, Mackillop WJ. Translating new medical therapies into societal benefit: the role of population-based outcome studies. JAMA 2008;300:2177-9.
8. Groome PA, Mackillop WJ. Uses of ecologic studies in the assessment of intended treatment effects. J Clin Epidemiol 1999;52:903-4.
9. Earle CC, Tsai JS, Gelber RD, Weinstein MC, Neumann PJ, Weeks JC. Effectiveness of chemotherapy for advanced lung cancer in the elderly: instrumental variable and propensity analysis. J Clin Oncol 2001;19:1064-70.
10. Vlahakes GJ. The value of phase 4 clinical testing. N Engl J Med 2006;354:413-15.
11. Avorn J. In defense of pharmacoepidemiology-embracing the yin and yang of drug research. N Engl J Med 2007;357:2219-21.
12. Juurlink DN. Rosiglitazone and the case for safety over certainty. JAMA 2010;304:469-71.
13. Renwick W, Pettengell R, Green M. Use of filgrastim and pegfilgrastim to support delivery of chemotherapy: twenty years of clinical experience. BioDrugs 2009;23:175-86.
14. Smith TJ, Khatcheressian J, Lyman GH, et al. 2006 Update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol 2006;24:3187-205.
15. American Society of Clinical Oncology. Recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. J Clin Oncol 1994;12:2471-508.
16. Vogel CL, Wojtukiewicz MZ, Carroll RR, et al. First and subsequent cycle use of pegfilgrastim prevents febrile neutropenia in patients with breast cancer: a multicenter, double-blind, placebo- controlled phase iii study. J Clin Oncol 2005;23:1178-84.
17. Holmes FA, Jones SE, O'Shaughnessy J, et al. Comparable efficacy and safety profiles of once-per-cycle pegfilgrastim and daily injection filgrastim in chemotherapy-induced neutropenia: a multicenter dose-finding study in women with breast cancer. Ann Oncol 2002;13:903-9.
18. Mattioli R, Gridelli C, Castellanos J, et al. Use of pegfilgrastim support on day 9 to maintain relative dose intensity of chemotherapy in breast cancer patients receiving a day 1 and 8 cmf regimen. Clin Transl Oncol 2009;11:842-8.
19. Liu MC, Demetri GD, Berry DA, et al. Dose-escalation of filgrastim does not improve efficacy: clinical tolerability and longterm follow-up on calgb study 9141 adjuvant chemotherapy for node-positive breast cancer patients using dose-intensified doxorubicin plus cyclophosphamide followed by paclitaxel. Cancer Treat Rev 2008;34:223-30.
20. Crawford J, Dale DC, Lyman GH. Chemotherapy-induced neutropenia: risks, consequences, and new directions for its management. Cancer 2004;100:228-37.
21. Duff JM, Leather H, Walden EO, LaPlant KD, George TJ Jr. Adequacy of published oncology randomized controlled trials to provide therapeutic details needed for clinical application. J Natl Cancer Inst 2010;102:702-5.